ASX-listed Bioxyne’s wholly-owned subsidiary BLS Wholesalers has launched its CanxChange trading platform in Australia with more than A$10 million of leads uploaded in its first week of operation.
The B2B platform is invite only and built to enable pharmacies, licensed manufacturers and cultivators to transact in a secure and user-friendly environment.
BLS CEO Sam Watson described CanxChange as “a sophisticated technology platform marketplace solution to help licensed businesses navigate the highly regulated environment safely, with greater transparency and ease”.
He added: “We have launched CanxChange to target the $500m-plus medicine specials market in Australia, including medicinal cannabis.
Read more at
BLS launches B2B trading platform CanxChange with $10m sales pipeline in week one
